Anti-hepatitis C virus drugs Market status Biological activity In vitro study Feature
ChemicalBook > CAS DataBase List > dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate

dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate

Anti-hepatitis C virus drugs Market status Biological activity In vitro study Feature
Product Name
dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
CAS No.
1009119-64-5
Chemical Name
dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
Synonyms
EBP 883;CS-1933;Daklinza;daclatavir;Dacaltasvir;Daclatasvir;Dhaka He Wei;Daclatasvir-d16;Daclatasvir/EBP883;Daclatasvir, >=98%
CBNumber
CB52515028
Molecular Formula
C40H50N8O6
Formula Weight
738.88
MOL File
1009119-64-5.mol
More
Less

dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate Property

Boiling point:
1071.2±65.0 °C(Predicted)
Density 
1.249
pka
10.92±0.46(Predicted)
More
Less

Safety

Safety Statements 
24/25
HS Code 
29332900
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
23730
Product name
Daclatasvir
Purity
≥95%
Packaging
5mg
Price
$45
Updated
2021/12/16
Cayman Chemical
Product number
23730
Product name
Daclatasvir
Purity
≥95%
Packaging
10mg
Price
$81
Updated
2021/12/16
Cayman Chemical
Product number
23730
Product name
Daclatasvir
Purity
≥95%
Packaging
25mg
Price
$180
Updated
2021/03/22
Cayman Chemical
Product number
23730
Product name
Daclatasvir
Purity
≥95%
Packaging
50mg
Price
$338
Updated
2021/03/22
TRC
Product number
D101500
Product name
Daclatasvir
Packaging
100mg
Price
$130
Updated
2021/12/16
More
Less

dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate Chemical Properties,Usage,Production

Anti-hepatitis C virus drugs

Daclatasvir (Daklinza) has obtained "priority review" status, combined with sorafenib for the treatment of genotype III adult patients with chronic hepatitis C. Daklinza has been the first drug that has been proved of being effective in the treatment of genotype III hepatitis C virus infection without the co-administration with interferon or ribavirin. Interferon and ribavirin are two drugs approved by FDA for the treatment of hepatitis C virus infection. Hepatitis C is a viral disease that can cause inflammation of the liver, resulting in decreased liver function or liver failure. Most patients infected with hepatitis C have no symptoms until liver damage becomes apparent, which may take several years. Globally, genotype III hepatitis C is the second most common genotype of hepatitis C after genotype 1 hepatitis C and is considered to be one of the most refractory genotype diseases. Daklinza is a pan-genotype NS5A replication complex inhibitor, with efficacy of inhibition of RNA replication and viral assembly, dual antiviral effect. For in vitro studies, Daklinza has been demonstrated to have anti-viral effect against genotype 1~6 hepatitis C virus. Daklinza is accompanied by a warning that the combination of amiodarone, Daklinza and Sofosbuvir may cause severe reduced heart rate. Daklinza is an oral tablet with the recommended dose of 60 mg for 1 times/d, in conjunction with Sofosbuvir for a total of 12 weeks.
【Research and development company】 Bristol-Myers Squibb.
【Patent Literature】 WO 2008021927A2 (August 9, 2007).
【Time of marketing】 July 24, 2015 listed in the United States, trade name Daklinza.
【Indications】 Used in combination with Sofosbuvir for the treatment of genotype 3 chronic hepatitis C (HCV) infection.
【Mechanism of action】 HCV nonstructural protein 5A (NS5A) inhibitors. Adverse reactions: headaches and fatigue.
【Formulation and specifications】 Tablets, 30 and 60mg.
 
Figure 1 the structure of Daklinza
The above information is edited by the Dongfang of Chemicalbook. (2016-03-03)

Market status

Daklinza is an inhibitor of hepatitis C virus (HCV) NS5A that is useful in the treatment of genotype 3 chronic hepatitis C infection.
On July 24, 2015, the FDA approved the chronic hepatitis C drug (Bristol-Myers Squibb) for marketing.
The FDA approval process of Daklinza (Bristol-Myers Squibb) has undergone twists and turns. It has been once rejected by the FDA, but finally approved in mid – 2015. The FDA approved the combination of Daklinza and Sofosbuvir for the treatment of hepatitis C gene type 3 patients.
In fact, as early as before the FDA approval, Daklinza had been approved for marketing in Japan, the European Union and South Korea and other countries. In 2014, Japanese health sector approved the application of Daklinza and asunaprevir (Sunvepra) for the treatment of genotype 1 infection. The European Union also approved Daclatasvir to be used in combination with other drugs in the treatment of HCV genotypes 1, 2, 3 and 4 in 2014. Daclatasvir is the first NS5A complex inhibitor approved by European Union (EU). When used in combination with other drugs, compared with the treatment combination of interferon and ribavirin which takes 48 weeks, it has a shorter duration of treatment (12 weeks or 24 weeks).
Daclathavir monotherapy is not recommended, the current mainstream protocol is combination therapy of dacastavir+ sofosbuvir, which is characterized by good efficacy, higher SVR, small side effects and further shortened treatment cycle than other options.
 
Figure 2 Daclatasvir tablets from United States Bristol-Myers Squibb Company

Biological activity

Daclatasvir (BMS-790052) is a highly selective HCV NS5A inhibitor with an EC50 of 9-50 pM. It acts on the infectious virus of various HCV replication genotypes and JFH-1 genotype 2a in cell cultures. Phase III;

In vitro study

BMS-790052 is one of the most potent HCV replication inhibitors reported so far with EC50 values of 50 and 9 pM on HCV genotype 1a and 1b replicons, respectively. BMS-790052 treatment index (CC50/EC50) is 105 or more. It has no effect on the 10 RNA and DNA viruses in group I with EC50 being greater than 10 μM. BMS-790052 is only effective in the treatment of HCV. BMS-790052 acts on the Huh7 cells containing the HCV genotype 1b replicon and BMS-790052 inhibits transient and stable HCV chromosome replication with an EC50 of 1-15 pM. BMS-790052 (100 pM or 1 nM) changes the subcellular localization and biochemical structure of NS5A. BMS-790052 can inhibit the heterozygous replicon containing HCV genotype-4 NS5A gene with an EC50 of 7-13 pM. The NS5A residue 30 in the heterozygous replicon is an important site for selection of resistance to BMS-790052.

Feature

BMS-790052 is a first-class, highly selective hepatitis C virus (HCV) NS5A inhibitor with an EC50 range at picomolar.

Uses

Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).

Definition

ChEBI: A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.

dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate Suppliers

Shanghai Boyle Chemical Co., Ltd.
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2926
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833- ;010-82848833-
Fax
86-10-82849933
Email
jkinfo@jkchemical.com;market6@jkchemical.com
Country
China
ProdList
96815
Advantage
76
ChemFuture PharmaTech (Jiangsu) Ltd
Tel
0510-85386188;0510-85386988-8021
Fax
86 510 85386988-8017
Email
Sales@chemfuture.cn;Sales@chemfuture.cn
Country
China
ProdList
811
Advantage
65
Chembest Research Laboratories Limited
Tel
021-20908456-
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
5947
Advantage
61
Nanjing Chemlin Chemical Co., Ltd
Tel
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
20007
Advantage
64
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32358
Advantage
50
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783;
Fax
+86 (531) 55696010 QQ 1762738062
Email
sales@trio-pharmatech.com (International market);trio@trio-pharmatech.com(Domestic market)
Country
China
ProdList
1856
Advantage
62
BOC Sciences
Email
info@bocsci.com
Country
United States
ProdList
21113
Advantage
65
T&W GROUP
Tel
021-61551611-
Fax
+86 21-50676805
Email
contact@trustwe.com
Country
China
ProdList
9758
Advantage
58
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9914
Advantage
58
More
Less

View Lastest Price from dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate manufacturers

Hebei Minshang Biotechnology Co.,Ltd
Product
Daclatasvir 1009119-64-5
Price
US $1.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
500ton/month
Release date
2018-09-25
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Daclatasvir 1009119-64-5
Price
US $0.00/Kg/Drum
Min. Order
1KG
Purity
98%-102%
Supply Ability
50kgs
Release date
2021-08-13
Zhuozhou Wenxi import and Export Co., Ltd
Product
Daclatasvir 1009119-64-5
Price
US $15.00-10.00/KG
Min. Order
1KG
Purity
99%+ HPLC
Supply Ability
Monthly supply of 1 ton
Release date
2021-07-10

1009119-64-5, dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamateRelated Search:


  • diMethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)
  • Daclatasvir
  • EBP 883
  • N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester
  • dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
  • Daclatasvir/EBP883
  • daclatavir
  • DiMethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-iMidazole-4, 2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-Methyl-1-oxobutane-2, 1-diyl)dicarbaMate (Related Reference)
  • Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester
  • N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester Daclatasvir BMS 790052
  • Dacaltasvir
  • Daklinza
  • Daclatasvir-d16
  • Dhaka He Wei
  • BMS-790052(Daclatasvir)
  • BMS-790052;EBP 883;BMS 790052
  • CS-1933
  • Daclatasvir, >=98%
  • Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))
  • Daclatasvir, 99%, Highly selective HCV NS5A inhibitors
  • dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-d
  • dimethyl(2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazolChemicalbooke-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
  • 1009119-64-5
  • 1009119-94-5
  • C40H50N8O6
  • C41H52N8O6
  • API
  • Inhibitors